Frontiers in CNS & Oncology Medicinal Chemistry

Topics: Medicinal Chemistry, Keywords: CNS, Cancer

Date: /7/8/9/ October 2007, Siena, Italy, Europe

Web Site, Contact: ascefmc-italy2007@sienabiotech.it

  

Official Information:

This 3 day meeting will bring together medicinal chemists from around the world to share exciting new results in CNS and oncology medicinal chemistry presented by leading industrial and academic research groups.

Topics:

• Multi-target-directed drugs for neurodegeneration
• Identification and optimisation of a novel series of selective 5HT2c antagonists
• Fragment-based lead generation and structure-based design for the discovery of high affinity beta-secretase inhibitors
• Selective sigma ligands and their role in neurodegeneration
• Design and SAR of potent, selective 5-HT6 Ligands and their potential utility as CNS disease therapeutics
• The MAO's long march: from toxic first-generation drugs to isoform-selective, reversible and multitarget inhibitors
• Design of Potent and Selective Memapsin 2 (ß-Secretase) Inhibitors for Alzheimer's Disease
• Discovery of Orally Active Nociceptin Receptor Agonists for the Management of Anxiety and Cough
• The discovery of a novel series of alpha7 nAChR agonists
• Protein misfolding and neurodegeneration
• Discovery of mGlu2/3 Receptor Agonists for the Treatment of Psychiatric Disorders
   
• Epigenetic small molecule modulators and cancer: an overview
• Mother Nature's Gifts to Cancer Chemotherapy
• Cancer Drug Discovery from Marine Cyanobacteria using Mechanism-Based and Mechanism-Blind Approaches
• Inhibitors of Apoptosis Proteins: Application of Structure Based Drug Design to the Taming of a Protein-Protein Interaction Target
• Small molecule kinases inhibitors: from virtual screening to in vitro and in vivo studies
• DNA minor groove binders (MGB) and tubulin inhibitors as antitumour agents
• Histone Deacetylase Inhibitors
• Aurora Kinase Inhibition: Identification and Expansion of Novel Scaffolds Leading to a Potent and Selective Compound with Favourable Antitumour Kinase Inhibition Profile